Sartorius Stedim Biotech (DIM) AI Stock Analysis

• Market Cap: €18.53B
• Dividend Yield: 0.36%
• Average Volume (3M): 55.20K
• Price to Earnings (P/E): 90.7
• Beta (1Y): 1.52
• Revenue Growth: 5.21%
• EPS Growth: -23.23%
• Country: FR
• Employees: 9,961
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.16
• Shares Outstanding: 97,330,410
• 10 Day Avg. Volume: 44,750
• 30 Day Avg. Volume: 55,205
• PEG Ratio: 5.61
• Price to Book (P/B): 4.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 32.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €234.75
• Price Target Upside: 23.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 62 Neutral
• Price Target: €208.00 ▲(9.27%Upside)

The overall stock score of 62 reflects a solid financial performance and effective cash flow management as key strengths. However, the stock's high valuation and technical indicators pointing to short-term bearish trends present risks. The absence of notable earnings call insights or corporate events limits additional positive or negative influences on the score.

Sartorius Stedim Biotech Business Overview & Revenue Model

Company Description

Sartorius Stedim Biotech (DIM) is a leading international pharmaceutical and laboratory equipment supplier, specializing in the development and manufacturing of products and services for the biopharmaceutical industry. The company is part of the Sartorius Group and focuses on providing comprehensive solutions for bioprocessing, including filtration, fermentation, cell cultivation, purification, and fluid management. Its products and services cater to the needs of pharmaceutical companies, biotechnology firms, and research institutions globally.

How the Company Makes Money

Sartorius Stedim Biotech generates revenue through the sale of its diverse range of bioprocessing equipment and consumables. Key revenue streams include the sale of filtration systems, fermentation and cell culture systems, purification products, and fluid management solutions. The company also earns money from providing related services, such as validation, qualification, and maintenance support. Sartorius Stedim Biotech maintains strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies to enhance its product offerings and expand its market reach. Additionally, the company invests in research and development to innovate and improve its products, ensuring sustained demand and growth in the competitive biotech industry.

Sartorius Stedim Biotech Financial Statement Overview

Summary

Sartorius Stedim Biotech presents a solid financial profile with strong revenue growth and margins, complemented by effective cash flow management and a stable balance sheet. While profitability metrics like net profit margin and return on equity could improve, the company's financial health is robust.

Income Statement

The income statement shows a stable revenue base with a modest growth rate of 2.8% in the latest TTM compared to the previous annual period. Gross profit margin is strong at 43.9%, indicating effective cost management. However, the net profit margin is relatively low at 7.1%, suggesting potential pressure on net earnings. EBIT and EBITDA margins are healthy at 15.6% and 25.5%, respectively, reflecting robust operating performance.

Balance Sheet

The balance sheet indicates a moderate debt-to-equity ratio of 0.74, which suggests a balanced approach to leverage. Return on equity stands at 5.1%, pointing to room for improvement in generating returns from equity. The equity ratio is reasonable at 47.8%, reflecting a solid equity foundation. Overall, the balance sheet is stable, though the company could enhance its ROE.

Cash Flow

Cash flow analysis reveals a significant 22.8% growth in free cash flow over the previous annual period, highlighting improved cash generation. The operating cash flow to net income ratio is strong at 4.3, indicating effective cash conversion. The free cash flow to net income ratio of 2.9 further underscores efficient cash flow management. Overall, the company demonstrates robust cash flow performance.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.78B	2.78B	3.49B	2.89B	1.91B
Gross Profit	1.21B	1.23B	1.83B	1.55B	1.00B
EBITDA	670.50M	755.70M	1.35B	811.96M	623.79M
Net Income	175.10M	309.70M	876.10M	414.40M	335.93M
Balance Sheet
Total Assets	8.26B	7.74B	5.07B	3.95B	3.07B
Cash, Cash Equivalents and Short-Term Investments	688.80M	126.10M	133.00M	237.35M	69.61M
Total Debt	2.87B	3.68B	1.14B	625.52M	586.78M
Total Liabilities	4.23B	5.07B	2.55B	2.22B	1.59B
Stockholders Equity	3.99B	2.64B	2.45B	1.66B	1.46B
Cash Flow
Free Cash Flow	475.30M	156.10M	181.70M	371.98M	257.69M
Operating Cash Flow	815.10M	629.70M	612.30M	695.97M	416.88M
Investing Cash Flow	-340.00M	-2.72B	-957.50M	-465.23M	-621.12M
Financing Cash Flow	84.90M	1.99B	220.70M	-71.71M	234.07M

Sartorius Stedim Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 190.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Negative. The current price of 190.35 is below the 20-day moving average (MA) of 200.11, below the 50-day MA of 198.48, and below the 200-day MA of 193.49, indicating a bearish trend. The MACD of -1.28 indicates Positive momentum. The RSI at 37.23 is Neutral, neither overbought nor oversold. The STOCH value of 6.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:DIM.

Sartorius Stedim Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIRP	76 Outperform	€2.97B	20.43	14.95%	0.41%	12.07%	20.48%
ERF	74 Outperform	€11.18B	28.78	9.66%	0.98%	6.70%	32.29%
BIM	72 Outperform	€14.00B	32.30	10.86%	0.76%	8.31%	21.00%
SAN	71 Outperform	$101.37B	18.71	7.34%	4.72%	-4.62%	2.88%
IPN	67 Neutral	€8.82B	25.51	8.89%	1.31%	8.73%	-46.34%
DIM	62 Neutral	€18.53B	90.66	5.24%	0.36%	5.21%	-23.23%
Sector *	55 Neutral	€4.62B	17.03	-50.16%	3.66%	15.32%	-9.52%

Sartorius Stedim Biotech Corporate Events

Sartorius Stedim Biotech Releases 2024 Universal Registration Document

Sartorius Stedim Biotech has announced the availability of its 2024 Universal Registration Document, which includes the group’s business development details for 2024 and the 2025 forecast. This document, now accessible on their investor relations page, also contains the consolidated financial statements for the year ended December 31, 2024. The release of this document provides stakeholders with comprehensive insights into the company’s financial and strategic positioning, potentially impacting investor confidence and industry standing.